This Multibagger Pharma Giant’s Subsidiary Becomes First Fully NABL Accredited Company, Bags 2 Prestigious Awards for Diagnostic Excellence
Over the past year, the stock has delivered a return of 27.39 per cent, while the three-year return is 171.38 per cent.
One of the company’s subsidiaries, Lupin Diagnostics Limited, has become the first 100 per cent NABL accredited company in the world after setting up its greenfield labs. This achievement not only demonstrates the company’s commitment to providing efficient and effective diagnostic services, but also reiterates its position in the diagnostics market. Ravindra Kumar, CEO of Lupin Diagnostics stated that this accreditation is a testimony of the team’s commitment to patient care and their vision to make lives healthier.
The company has won many awards such as 'Patient-Centric Diagnostic Laboratories Company of the Year' at IHW 3rd Patients First Award 2024 and 'Emerging Diagnostics Chain of the Year' at Diagnostics Innovation and Excellence Award 2024. Lupin Diagnostics, established in December 2021, has a National Reference Laboratory at Navi Mumbai and provides more than 3000 tests in various fields of medicine. The company is growing its network and improving healthcare delivery through constant improvement and innovation.
DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, download the service details here.
Lupin Limited, based in Mumbai, is one of the world's largest transnational pharmaceutical companies with a presence in more than 100 countries, including the U.S., India, and South Africa. The company is a global leader in the development and commercialization of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). Lupin is one of the largest companies in the therapeutic segments of cardiovascular, diabetology, asthma, pediatrics, and the central nervous system. It is the world’s largest producer of anti-TB and cephalosporins. The company has 15 manufacturing facilities and 7 research centers across the globe with over 23,000 employees.
Lupin's strategic focus areas include product portfolio expansion, complex generics, and R&D growth. Some of the recent events include the introduction of new products in diabetes care, GI, derma and vaccines and strategic deals to enhance the business. Lupin’s mission to improve patient health is reflected in its efforts to innovate and offer quality products.
As of April 23, 2025, the stock price of Lupin Limited stands at Rs 2,090.95. The stock has a 52-week high of Rs 2,396.30 and a 52-week low of Rs 1,555.10. The company's market capitalisation is Rs 93,454 crores. Over the past year, the stock has delivered a return of 27.39 per cent, while the three-year return is 171.38 per cent. Lupin trades at a price-to-earnings (P/E) ratio of 31.71 and offers a dividend yield of 1.02 per cent.
Investors should keep an eye on this Large-Cap pharmaceutical company.
Disclaimer: The article is for informational purposes only and not investment advice